报价延迟最少15分钟:2026/07/15 04:58 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
28.78
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-9.10/-4.34
|
|
企业价值
1.76B
|
| 资产负债 |
|
每股账面净值
5.32
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.00M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies. |
